These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 18623378

  • 1. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 15; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 3. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
    Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H.
    Lung Cancer; 2008 Mar 15; 59(3):377-84. PubMed ID: 17905465
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 15; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H.
    Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):565-73. PubMed ID: 19123003
    [Abstract] [Full Text] [Related]

  • 6. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N.
    J Thorac Oncol; 2007 Oct 15; 2(10):902-6. PubMed ID: 17909351
    [Abstract] [Full Text] [Related]

  • 7. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
    Li GF, Deng SJ, Weng WW, Guo G, Chen N.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep 15; 30(9):2131-3. PubMed ID: 20855270
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ.
    Clin Lung Cancer; 2013 Jul 15; 14(4):418-24. PubMed ID: 23291258
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct 15; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 10. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
    Pezzetta E, Stupp R, Zouhair A, Guillou L, Taffé P, von Briel C, Krueger T, Ris HB.
    Eur J Cardiothorac Surg; 2005 Jun 15; 27(6):1092-8. PubMed ID: 15896624
    [Abstract] [Full Text] [Related]

  • 11. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D.
    Lung Cancer; 2013 Nov 15; 82(2):324-9. PubMed ID: 23993732
    [Abstract] [Full Text] [Related]

  • 12. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC, Sheen SS.
    Lung Cancer; 2010 May 15; 68(2):288-94. PubMed ID: 19560836
    [Abstract] [Full Text] [Related]

  • 13. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M, Cejas P, Moreno V, Belda-Iniesta C, López R, Nistal M, Feliu J, De Castro Carpeño J.
    Int J Oncol; 2012 Jun 15; 40(6):2104-10. PubMed ID: 22344449
    [Abstract] [Full Text] [Related]

  • 14. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O, Ozdemir P, Veral A, Uluer H, Ozhan MH.
    Asian Pac J Cancer Prev; 2013 Jun 15; 14(8):4679-83. PubMed ID: 24083725
    [Abstract] [Full Text] [Related]

  • 15. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB.
    J Clin Oncol; 2003 May 01; 21(9):1752-9. PubMed ID: 12721251
    [Abstract] [Full Text] [Related]

  • 16. Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer?
    Park BB, Park JO, Kim H, Ahn YC, Choi YS, Kim K, Kim J, Shim YM, Ahn JS, Park K.
    Lung Cancer; 2006 Sep 01; 53(3):323-30. PubMed ID: 16844258
    [Abstract] [Full Text] [Related]

  • 17. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P, Herndon J, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.
    Cancer; 1996 Jun 01; 77(11):2393-9. PubMed ID: 8635112
    [Abstract] [Full Text] [Related]

  • 18. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec 01; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 19. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
    Xie KJ, He HE, Sun AJ, Liu XB, Sun LP, Dong XJ.
    Asian Pac J Cancer Prev; 2014 Dec 01; 15(6):2591-6. PubMed ID: 24761869
    [Abstract] [Full Text] [Related]

  • 20. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    Cancer Chemother Pharmacol; 2011 Oct 01; 68(4):935-44. PubMed ID: 21298384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.